Judge triples damages to nearly $290M; whistleblower case spotlights CVS Caremark’s price reporting and tests False Claims Act penalties
CVS Caremark (Courtesy Wikipedia)Philadelphia, Pennsylvania (Times Media Service) – A federal judge ordered CVS Health’s pharmacy benefit manager, CVS Caremark, to pay nearly $290 million after a whistleblower said the company inflated drug cost data and overcharged Medicare—an important test of how courts police Medicare fraud and the opaque practices of pharmacy benefit managers.
What the court decided and why it matters
In a Philadelphia federal court, Chief U.S. District Judge Mitchell Goldberg tripled earlier damages to $285 million and added roughly $4.9 million in civil penalties under the False Claims Act. The ruling followed a June bench trial that found CVS Caremark submitted—or caused the submission of—misleading drug price information that pushed costs higher for Medicare Part D. While the court did not find direct evidence of intentional deception, it said the conduct met the legal standard for reckless disregard, a key trigger in Medicare fraud cases.
The judgment stems from a long-running lawsuit that began more than a decade ago. The judge emphasized that Medicare relies on accurate price reporting to set payments for prescription drugs. When those numbers are inflated, taxpayers foot the bill, seniors see higher premiums over time, and trust in the program erodes. That’s why the court said stiff penalties were needed—both to make the government whole and to deter future Medicare fraud.
CVS Caremark said it strongly disagrees with the decision and plans to appeal. The company argues the damages are excessive and that the dispute centers on complex federal rules for reporting prices—not any intent to commit Medicare fraud. Interest on the judgment will accrue while appeals play out, potentially increasing the total.
How the whistleblower says the scheme worked
The whistleblower is Sarah Behnke, a former Aetna Medicare Part D actuary. She alleged CVS Caremark reported higher prescription drug costs to the government than it actually paid retail pharmacies. That gap, she said, distorted the data Medicare uses to reimburse plans, a pattern consistent with Medicare fraud if it inflates federal spending.
Evidence at trial focused on plan years 2013 and 2014, with allegations that similar practices stretched back further. Behnke first filed the case in 2014. CVS would later acquire Aetna in 2018, after the conduct at issue. Those dates matter: they suggest the price reporting practices predated the merger and were embedded in earlier systems—a point the court weighed when it concluded the conduct reflected reckless disregard.
Under the False Claims Act, private citizens can sue on the government’s behalf and collect a percentage of any recovery. If the judgment stands, Behnke could receive a significant share—one reason Congress designed the law to uncover hidden Medicare fraud that government auditors might miss.
CVS Caremark’s response and the road to appeal
CVS Caremark insists it followed the rules that govern how pharmacy benefit managers report drug costs. It says differences between reported prices and pharmacy reimbursements reflect normal contracting practices, not Medicare fraud. The company indicates it has tightened compliance in recent years and that the period at issue was limited.
On appeal, CVS Caremark is expected to challenge both the legal standard and the size of the award. The central questions: Did the court correctly apply “reckless disregard” to label the conduct Medicare fraud? And were treble damages plus penalties proportional to the proven overcharges? Appellate judges will also look at the evidence window—primarily 2013–2014—and whether it justifies the scope of the penalties.
However the appeal goes, the verdict sends a message across the industry: inaccurate or misleading price data can lead to massive liabilities. For companies that manage Part D plans, the safest path is to align reported prices with what pharmacies are actually paid—exactly the kind of alignment that helps prevent Medicare fraud.
What it means for seniors, taxpayers, and drug prices
For seniors on fixed incomes, the link between courtrooms and co-pays can feel distant. But it’s real. Medicare’s formulas consider how much drugs cost plans. If data are inflated, payments trend up, and so can plan bids, premiums, and deductibles. Cracking down on Medicare fraud protects those formulas—and, over time, the monthly bills that millions of seniors pay.
Taxpayers also benefit when enforcement is strong. Every dollar lost to Medicare fraud is a dollar that can’t support benefits, shore up the program’s finances, or reduce the deficit. A case like this can push companies to improve internal controls, audit more aggressively, and disclose more about how prices are calculated.
Don’t expect instant savings at the pharmacy counter. Court rulings don’t flip a switch. But they do change behavior. Tighter audits and clearer rules can reduce the risk of future Medicare fraud, and that can help keep long-term costs in check for families and the federal budget.
PBMs under new scrutiny—and the False Claims Act’s bite
Pharmacy benefit managers (PBMs) sit between drugmakers, pharmacies, and health plans, negotiating prices and managing formularies. Critics say the system is too opaque, allowing spread pricing and fees that are hard to trace. This case adds weight to calls for transparency and stronger guardrails aimed at preventing Medicare fraud before it starts.
Lawmakers in both parties have floated reforms that would force PBMs to disclose more about how they set reimbursements and retain fees. Enforcement is also rising elsewhere: in a separate case last month, a federal judge ordered CVS’s Omnicare unit to pay nearly $949 million over invalid prescriptions—different facts, same statute. Together, these outcomes show that courts are willing to use the False Claims Act to tackle alleged abuses in federal health programs and to penalize behavior that looks like Medicare fraud.
For plan sponsors and employers, the ruling is a reminder to revisit contracts and demand clear, auditable price reporting. If the numbers can’t be verified, the risk of hidden costs—or worse, Medicare fraud—goes up.
Reaction and nationwide impact
Patient advocates and watchdog groups praised the verdict, saying it strengthens the case for PBM transparency and tougher oversight. They argue that fast, firm enforcement reduces opportunities for Medicare fraud and aligns costs with reality. Conservative budget hawks say it’s a straightforward win for accountability: when a company inflates bills, taxpayers shouldn’t carry the tab.
Insurers and plan sponsors are likely to push PBMs for cleaner data pipelines and real-time reconciliation between reimbursements and reported prices. That posture could spread across the market as other firms look to avoid litigation risk and the perception of Medicare fraud.
State and federal lawmakers will almost certainly cite this case when hearings resume on drug pricing and PBM reform. Expect proposals that require more detailed reporting to Medicare, routine audits of price submissions, and limits on spread pricing—policies designed to keep Medicare fraud in check while protecting seniors’ access to medicines.
